Gallic acid-mitochondria targeting sequence-H₃R₉ induces mitochondria-targeted cytoprotection

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Pharmacology

Background:

• Selective drug delivery to mitochondria is crucial for enhancing therapeutic efficacy.
• Mitochondria play a key role in cellular health and disease pathogenesis.
• Antioxidant therapies are vital for mitigating oxidative stress-related damage.

Purpose of the Study:

• To develop and evaluate a novel mitochondria-targeting vehicle with dual therapeutic functions.
• To assess the efficacy of gallic acid (GA)-mitochondria targeting sequence (MTS)-H3R9 as a therapeutic agent.
• To investigate the compound's cell penetration, lysosomal escape, and antioxidant properties.

Main Methods:

• Synthesis and characterization of GA-MTS-H3R9.
• In vitro cell viability assays using AC16 cells.
• Assessment of cell penetration, intercellular uptake, and lysosomal escape.
• Evaluation of mitochondrial targeting and antioxidant activity.
• Measurement of reactive oxygen species (ROS) production and mitochondrial membrane potential.

Main Results:

• GA-MTS-H3R9 demonstrated superior rescue action in viability assays compared to MTS-H3R9.
• The compound exhibited enhanced cell penetration, intercellular uptake, and efficient escape from lysosomes.
• Targeting of GA-MTS-H3R9 to mitochondria in AC16 cells was confirmed.
• Mitochondrial accumulation of GA-MTS-H3R9 alleviated cell damage by reducing ROS and stabilizing mitochondrial membrane potential.
• GA-MTS-H3R9 showed significantly increased cytoprotective and anticancer effects compared to MTS-H3R9.

Conclusions:

• GA-MTS-H3R9 serves as an effective mitochondria-targeting vehicle with potent antioxidant capabilities.
• The compound holds significant therapeutic potential for diseases involving mitochondrial dysfunction and oxidative stress, including cardiovascular diseases.
• This dual-action agent offers a promising strategy for targeted disease treatment.